Research & Education

Immunotherapy: A New Standard of Care in NSCLC

Monday, May 15, 2017 - 6:00PM CEST (Central European Summer Time) - Recording Available



Federico Cappuzzo, MD
Director of Medical Oncology
Department of Oncology and Hematology
Ospedale Santa Maria delle Croci
Ravenna, Italy

Pr Françoise Mornex, MD, PhD
Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France

Name of Reviewer(s): 


Laurie Gaspar, MD –Nothing to Disclose

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose


Name of Activity: 


Immunotherapy: A New Standard of Care in NSCLC

Date of Activity:




COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Chair:Pr Francoise Mornex, MD, PhD

Grant Research/Honoraria: IBA, Merck, Roche and Lilly


Speaker: Federico Cappuzzo, MD

Nothing to Disclose

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list:

About the Program:

Cancer immunotherapy is emerging as one of the most promising areas of cancer research and treatment. Overall, the goal of cancer immunotherapy is to stimulate a patient's immune system to recognize cancer cells as foreign and attack them. Data from recent phase III trials established immunotherapy as the new standard of care as first-line therapy in selected patients with non-small cell lung cancer (NSCLC) and irrespective of PD-L1 expression in second-line setting.  The aim of this webinar is to present the most recent data on checkpoint inhibitors and how this innovative approach is changing the paradigm for NSCLC therapy.

Accordingly, in this program we will:

  • illustrate how immunotherapy is changing the algorithm of NSCLC therapy;
  • address how to select appropriate patients for immunotherapy;
  • examine the future development of immunotherapy in NSCLC.

 After viewing this program, attendees will:

  • recognize the current role of immunotherapy in the first-line and second-line treatment of advanced stage NSCLC;
  • apply selection criteria to identify patients most likely to benefit from immunotherapy;
  • recognize the major clinical trials underway to further develop the utility of immune checkpoint inhibitors.

 Registration is taken on first-come, first served basis.

Following the didactic presentation, Dr. Cappuzzo and Dr. Mornex will answer questions and address comments from the audience.  There will be ample opportunity for Attendees to submit questions and comments via internet chat.

In order to receive CME credit, attendees must fill out a program evaluation.

Financial/Commercial and Conflicts of Interest Disclosures

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)


Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

Attendees can now view IASLC Live webinars via their mobile device. Downloading of the Cisco WebEx Meetings app is required.

  • For Droid users, download the Cisco WebEx Meetings app from the Google Play Store. 
  • For iPad & iPhone users, download the Cisco WebEx Meetings app from the App Store.

Once the app is installed on your device you will need to enter the event number for each session. Registration is required for all IASLC webinars.

Use the Time Zone Converter